Latest news with #Tune
USA Today
03-07-2025
- Sport
- USA Today
2025 Arizona Cardinals training camp roster preview: QB Clayton Tune
We will preview every player on the Cardinals roster leading up to training camp. This is about QB Clayton Tune. The Arizona Cardinals report to training camp on July 22 and begin the process of preparing for the regular season, forming the roster and determining starting jobs and roles on the team. Leading up to the start of camp, we will take a look at every player on the offseason roster, their background, their contract, their play in 2024, questions they face and their roster outlook. This focuses on quarterback Clayton Tune. Clayton Tune background, 2024 season Tune enters his third NFL season. He was drafted in the fifth round in 2023 out of Houston. He has been the Cardinals' backup quarterback for two seasons. He had one start in 2023 preceding Kyler Murray's return from his ACL injury. Last year, the Cardinals traded for Desmond Ridder but Tune beat him out for the backup job in training camp and the preseason. Last season, he appeared in six games, playing 31 snaps. He mostly entered games for kneeldowns or quarterback sneaks. He completed his only two pass attempts for eight yards and had minus-four yards on seven rushing attempts, although he did pick up two first downs. Clayton Tune 2025 contract details, cap hit Tune will make $1.03 million in salary in 2025 if he makes the active roster. He will count $1.12 million against the salary cap. Questions he faces, roster outlook Tune find himself is a tough situation in 2025. The Cardinals signed veteran quarterback Jacoby Brissett to a two-year contract this offseason with his 2025 salary fully guaranteed. Brissett will be Kyler Murray's backup. Also, in two seasons under head coach Jonathan Gannon, the Cardinals have never carried more than two quarterbacks on the 53-man roster, so Tune will have to show extraordinary growth to make the roster. He is currently a longshot to make the team but is probably a lock for the practice squad, considering how Gannon has spoken about Tune. Get more Cardinals and NFL coverage from Cards Wire's Jess Root and others by listening to the latest on the Rise Up, See Red podcast. Subscribe on Spotify, YouTube or Apple podcasts.
Yahoo
09-06-2025
- Business
- Yahoo
Showcasing the First Offer Server for In-App Monetization: GoKart Unveils New Website
LOS ANGELES, June 9, 2025 /PRNewswire/ -- GoKart launched its completely redesigned website at showcasing the AdTech industry's first Offer Server for mobile monetization and in-app advertising that centralizes every direct and network offer into a single dashboard. See the LinkedIn announcement at: Built from the ground up, the new site clearly defines what an Offer Server is: a unified platform that serves every in-app deal, whether CPI, CPA, CPE, direct, or third-party, while also tracking, routing, and optimizing those offers in real time with built-in attribution and fraud protection. No more toggling between SDKs, spreadsheets, or multiple dashboards; GoKart brings your entire monetization stack together. When you're ready to dive deeper, you can schedule a live walkthrough in just a few clicks. "We set out to create more than just a website refresh," said Lenny Rabin, CEO & Founder of GoKart. "This new digital home reflects our mission: to demystify performance marketing and empower publishers with a single source of truth for every offer, no matter where it comes from." Connect with Lenny on LinkedIn: Here's a peek under the GoKart hood: An all-in-one Offer Hub serving both direct & third-party, rewarded & non-rewarded deals without switching tools. Real-Time Analytics & Attribution helps monitor campaign performance, user acquisition costs, and ROI instantly. No more waiting on delayed reports or manual spreadsheets. Effortless Integrations, plugging into AppsFlyer, Tune, Adjust (and your other MMPs) in minutes. Custom Targeting & Safeguards, allowing you to define audience rules and activate fraud protection automatically. Visitors can expect regular updates—thought-leadership articles on user acquisition strategies, customer success stories illustrating mobile monetization wins, and technical deep dives on campaign management. Ready to see GoKart in action? Book your demo now at About GoKartGoKart is the first off-the-shelf Offer Server and in-app campaign management platform built for maximum optionality. Whether you're working directly with advertisers, third-party networks, or a mix of both, GoKart's Offer Server, admin, and tracking capabilities put you in the driver's seat. By combining mobile monetization, attribution, and real-time analytics into one system, GoKart simplifies campaign management and drives revenue growth without custom engineering. View original content: SOURCE GoKart Sign in to access your portfolio
Yahoo
09-06-2025
- Business
- Yahoo
Showcasing the First Offer Server for In-App Monetization: GoKart Unveils New Website
LOS ANGELES, June 9, 2025 /PRNewswire/ -- GoKart launched its completely redesigned website at showcasing the AdTech industry's first Offer Server for mobile monetization and in-app advertising that centralizes every direct and network offer into a single dashboard. See the LinkedIn announcement at: Built from the ground up, the new site clearly defines what an Offer Server is: a unified platform that serves every in-app deal, whether CPI, CPA, CPE, direct, or third-party, while also tracking, routing, and optimizing those offers in real time with built-in attribution and fraud protection. No more toggling between SDKs, spreadsheets, or multiple dashboards; GoKart brings your entire monetization stack together. When you're ready to dive deeper, you can schedule a live walkthrough in just a few clicks. "We set out to create more than just a website refresh," said Lenny Rabin, CEO & Founder of GoKart. "This new digital home reflects our mission: to demystify performance marketing and empower publishers with a single source of truth for every offer, no matter where it comes from." Connect with Lenny on LinkedIn: Here's a peek under the GoKart hood: An all-in-one Offer Hub serving both direct & third-party, rewarded & non-rewarded deals without switching tools. Real-Time Analytics & Attribution helps monitor campaign performance, user acquisition costs, and ROI instantly. No more waiting on delayed reports or manual spreadsheets. Effortless Integrations, plugging into AppsFlyer, Tune, Adjust (and your other MMPs) in minutes. Custom Targeting & Safeguards, allowing you to define audience rules and activate fraud protection automatically. Visitors can expect regular updates—thought-leadership articles on user acquisition strategies, customer success stories illustrating mobile monetization wins, and technical deep dives on campaign management. Ready to see GoKart in action? Book your demo now at About GoKartGoKart is the first off-the-shelf Offer Server and in-app campaign management platform built for maximum optionality. Whether you're working directly with advertisers, third-party networks, or a mix of both, GoKart's Offer Server, admin, and tracking capabilities put you in the driver's seat. By combining mobile monetization, attribution, and real-time analytics into one system, GoKart simplifies campaign management and drives revenue growth without custom engineering. View original content: SOURCE GoKart Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13-05-2025
- Business
- Business Wire
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics
SYDNEY--(BUSINESS WIRE)--Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams' partnership and sets a benchmark for CRO–biotech partnerships. Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B. Share The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, accepted the award on behalf of Novotech at the Citeline Awards ceremony held on May 8, 2025, in Boston. Katie Tarashuck, Vice President of Finance at Tune Therapeutics, attended as a partner representative. Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and therapeutic expertise with Tune's innovative scientific platform and agile development strategy. 'This recognition from Citeline reflects not only the strength of our partnership with Tune Therapeutics but also the dedication of our global teams to help bring novel therapies to patients faster,' said Dr. John Moller, CEO of Novotech. 'We are honored to collaborate with visionary biotech companies like Tune and look forward to continuing to deliver clinical excellence across the development spectrum.' 'Tune is delighted to receive this partnership award with Novotech," said Dr. Heidi Zhang, Chief Development Officer at Tune Therapeutics. "Together, we have achieved a global first in bringing this epigenome editing therapy to the clinic, and new hope to over 250 million people living with CHB worldwide.' The award acknowledges Novotech's ability to align closely with biotech partners, applying its regulatory and therapeutic expertise to support the effective delivery of clinical trials across varied global settings. 'The strength of this collaboration,' added Dr. Zhang, 'lies in our shared commitment to transparency, willingness to confront challenges directly, and ability to act quickly and effectively as one team.' About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA. Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common and chronic diseases.
Business Wire
13-05-2025
- Business
- Business Wire
Novotech憑藉與Tune Therapeutics的策略合作榮膺Citeline CRO年度合作夥伴關係獎
澳洲雪梨--(BUSINESS WIRE)--(美國商業資訊)-- 作為一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司，Novotech有幸榮膺Citeline CRO年度合作夥伴關係獎。這項殊榮表彰了Novotech與表觀基因編輯龍頭企業Tune Therapeutics之間的策略合作，嘉許了雙方團隊之間的卓越合作夥伴關係，並為CRO與生物技術公司之間的合作夥伴關係樹立了業界新標杆。 Novotech 與 Tune Therapeutics 的合作重點是一項有潛力徹底改變慢性乙型肝炎治療格局的表觀遺傳療法的突破性臨床試驗計劃。 Share CRO年度合作夥伴關係獎旨在表彰CRO與製藥或生物技術公司之間的出色合作。為實現共同目標，雙方勠力同心，致力於推動臨床研究計畫的發展。 治療策略總監Sarah Anderson和業務開發副總監Steve Roan在2025年5月8日於波士頓舉行的Citeline頒獎典禮上代表Novotech受獎。Tune Therapeutics財務副總裁Katie Tarashuck作為合作夥伴代表出席了頒獎典禮。 Novotech和Tune Therapeutics之間的策略合作聚焦於一項開創性臨床試驗計畫，該計畫旨在推動表觀基因療法取得突破性進展，有望徹底改變慢性B型肝炎 (CHB) 的治療格局。雙方的合作夥伴關係將使Novotech的監管、營運和臨床方面的專業知識與Tune的創新科學研發平台和靈活開發策略深度融合。 Novotech執行長John Moller博士表示：「Citeline對我們的認可不僅體現了我們與Tune Therapeutics之間堅實的合作夥伴關係，同時也彰顯了我們的國際團隊致力於幫助患者更快地獲得新型療法的承諾。能與Tune等具有遠見卓識的生物技術公司合作，我們倍感榮幸。同時，我們也期待繼續在療法開發領域提供卓越的臨床服務。」 Tune Therapeutics開發長Heidi Zhang博士表示：「Tune很高興能與Novotech共同受獎。我們攜手進行了創新，將表觀基因組編輯療法融入臨床研究，為全球逾2.5億CHB患者帶來了新曙光。」 這項殊榮認可了Novotech與生物技術合作夥伴之間的通力合作能力，對於該公司運用其監管和臨床專業知識，在多樣化全球環境下有效展開臨床試驗給予肯定。 Zhang博士還表示：「合作的優勢在於我們共同承諾提高透明度、願意直迎挑戰，並能夠組建團隊以迅速有效地採取對策的能力。」 关于 Novotech Novotech是一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司，在藥物研發的各個階段提供指導，深受生物技術及中小型製藥公司的信賴。 Novotech業務涉及全球多個國家和地區，在亞太地區、北美和歐洲設有30多個辦事處，並與5000多個試驗中心建立了合作關係，透過提供關鍵臨床試驗資源網絡、廣泛接觸不同的受試者群體，幫助客戶加速將前沿的治療方法推向市場。 Novotech透過以客戶為中心的服務模式，將人員、流程和技術無縫整合，提供定制化解決方案，推動變革性的治療方法進入市場。Novotech採用真正的合作夥伴關係模式，堅定地致力於幫助客戶取得成功、推動創新並促進全球醫療保健的發展。Novotech憑藉卓越的臨床試驗執行和創新能力獲得了眾多業界榮譽，包括連續19年蟬聯Frost & Sullivan CRO年度公司獎 (Frost & Sullivan CRO Company of the Year)。Novotech在臨床以及法規方面深厚的專業知識，以及對本地市場的深刻洞察，使其能夠為臨床試驗的順利進行、資料分析的強化以及加速受試者招募策略方面提供支援。 Novotech與客戶攜手，將科學進步轉化為能夠改善全球健康狀況的治療方法，實踐推動創新、創造卓越成果的使命。
